Groundbreaking Results: Micot Pharma's MT200605 Achieves Primary Endpoint in Phase II Trial for Acute Ischemic Stroke Treatment

Micot Pharma, a leading pharmaceutical company, has announced positive topline data from the Phase II clinical trial of MT200605, a proprietary drug candidate for the treatment of acute ischemic stroke (AIS). The trial met its primary endpoint with statistically significant results, demonstrating the potential of MT200605 to revolutionize the treatment of AIS.

The Phase II trial was a multicenter, randomized, double-blind, placebo-controlled study that enrolled 360 subjects with acute ischemic stroke. The results showed that the proportion of patients achieving a modified Rankin Scale (mRS) score of 0–1 at 90 days was higher in both the medium- and high-dose MT200605 groups compared to the placebo group. Notably, the high-dose group achieved more than double the proportion of patients with mRS 0–1 compared to the placebo group, with a statistically significant between-group difference.

The trial also demonstrated a favorable safety profile, with no serious adverse events related to the investigational drug reported. Treatment-emergent adverse events of grade 3 or higher were evenly distributed among the groups, and no new safety risks were identified. This positive set of topline data provides a crucial clinical rationale for advancing MT200605 to the next stage of clinical development.

Micot Pharma's selection for the 18th World Stroke Congress (WSC 2026) will allow the company to share the non-clinical and Phase I results of MT200605 with global stroke experts. The WSC is a premier international academic platform in the field of stroke, bringing together leading global experts in stroke research and clinical practice to showcase cutting-edge research, clinical trials, and innovative therapeutic strategies.

The core competitiveness of MT200605 stems from its globally unique mechanism of action among clinical-stage stroke therapies. MT200605 is the only clinical-stage small-molecule agonist capable of crossing the blood-brain barrier, targeting the BDNF/TrkB pathway, and exerting neurorestorative activity. The drug achieves comprehensive intervention across the upstream, midstream, and downstream stages of ischemic brain injury via a single molecule, making it a promising treatment option for AIS.

MT200605's mechanism of action involves improving blood flow, limiting acute injury, and promoting repair. By modulating calcium signaling in vascular smooth muscle, MT200605 induces vasodilation, relieves secondary ischemia caused by microvascular spasm, improves microcirculation, and enhances cerebral perfusion. Additionally, MT200605 potently scavenges reactive oxygen species (ROS), limiting oxidative injury, and activates TrkB to attenuate excitotoxicity and reduce neuronal apoptosis.

The potential impact of MT200605 on the treatment of AIS cannot be overstated. Acute ischemic stroke is a leading cause of disability and death worldwide, with limited treatment options available. The current standard of care for AIS is primarily focused on clot-busting therapies, which have limited efficacy and are often associated with significant side effects. MT200605, with its unique mechanism of action and promising clinical results, may offer a new hope for patients with AIS.